BETOPTIC PILO SUMMARY
(betaxolol 0.25% / pilocarpine
hydrochloride 1.75% ophthalmic
Betoptic®Pilo Ophthalmic Suspension contains betaxolol hydrochloride, a cardiovascular (beta1) adrenoceptor antagonist and pilocarpine hydrochloride, a cholinergic parasympathomimetic agent. Betaxolol hydrochloride is a white, crystalline powder.
Betoptic®Pilo Ophthalmic Suspension is indicated for the reduction of elevated intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension who are insufficiently responsive to Betoptic®-S (failed to achieve target IOP determined after multiple measurements over time).
It is not known whether Betoptic®Pilo is equivalent in IOP lowering efficacy to the administration of Betoptic®-S 0.25% and pilocarpine 1.75% dosed separately. It is not known whether Betoptic®Pilo is equivalent to other beta-blockers given in combination with pilocarpine.
Published Studies Related to Betoptic Pilo (Betaxolol / Pilocarpine)
A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma. [1998.08]
PURPOSE: The author compares the effect of betaxolol, timolol, and pilocarpine on visual functions in patients with glaucoma... CONCLUSIONS: In spite of a greater pressure reduction, timolol did not have a more favorable effect on visual function. In the short-wave automated perimetry, the betaxolol did marginally better than timolol. The apparent dissociation between pressure reduction and protection of visual function deserves further study.
Ocular hypotensive efficacy and safety of a combined formulation of betaxolol and pilocarpine. 
PURPOSE: To evaluate the ocular hypotensive efficacy and safety of a fixed combination of betaxolol (0.25%) and pilocarpine (1.75%)... CONCLUSION: In patients requiring more than one ocular hypotensive agent, the combination of betaxolol and pilocarpine in a single formulation appears to be an effective and relatively safe agent. The use of this combination agent promises the potential for enhanced patient convenience.
Comparison of the postoperative intraocular pressure with Betagan, Betoptic, Timoptic, Iopidine, Diamox, Pilopine Gel, and Miostat. [1992.01]
A randomized, masked study measuring postoperative intraocular pressure at 4, 8, and 24 hours, two to seven days, and one month after planned extracapsular cataract extraction with posterior chamber lens implantation was conducted. Seven commonly used ocular hypotensive agents and a control, given at the completion of surgery, were compared: timolol maleate (Timoptic), levobunolol hydrochloride (Betagan), betaxolol hydrochloride (Betoptic), pilocarpine hydrochloride (Pilopine Gel), carbachol (Miostat), apraclonidine hydrochloride (Iopidine), acetazolamide (Diamox)...
Intraocular pressure reduction with topically administered pilocarpine, timolol and betaxolol in normal tension glaucoma. [1993.10]
The IOP-lowering effect of topical glaucoma medication has been studied mainly in eyes with ocular hypertension or high tension glaucoma. We tested the IOP-lowering effect of the commonly used topical medications (pilocarpine, timolol and betaxolol) in eyes with normal tension glaucoma... The results for 11 eyes participating in all three tests were similar to the results for the other eyes in the three test groups.
Clinical Trials Related to Betoptic Pilo (Betaxolol / Pilocarpine)
Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-Forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension. [Completed]
To evaluate the safety and efficacy of BETOPTIC S and Timolol Gel-forming solution in
pediatric patients. Patients will dose with study drug at 8 am and 8 pm daily for twelve
weeks. Patients will have vision tested, slit lamp exam, blood pressure and pulse checks at
each visit. Patients will have a dilated fundus exam and corneal measurements taken at first
and last visit.
Early Manifest Glaucoma Trial (EMGT) [Active, not recruiting]
The primary purpose is to compare the effect of immediate therapy to lower the intraocular
pressure (IOP) versus late or no treatment on the progression of newly detected open-angle
glaucoma, as measured by increasing visual field loss and/or optic disc changes.
The secondary purposes are to determine the extent of IOP reduction attained by treatment, to
explore factors that may influence glaucoma progression, and to describe the natural history
of newly detected glaucoma.
Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension [Completed]
Plasma renin values determine whether volume or vasoconstrictor (renin) factors predominate
in elevating blood pressure and are useful in selecting effective antihypertensive
The researchers hypothesize that:
1. Plasma renin-guided therapeutics will improve systolic and diastolic blood pressure
control in patients with untreated hypertension as well as in patients with treatment
refractory or resistant hypertension that are managed by Clinical Hypertension
2. Renin-guided therapeutics will reduce the number of medications required to maintain
blood pressure control to <140/90 mmHg in hypertensive patients receiving 3 or more
medications, while under the care of a Clinical Hypertension Specialist.
3. Renin-guided therapeutics selection will reduce the total cost of antihypertensive care
provided by Clinical Hypertension Specialists.
Page last updated: 2007-05-02